Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2868 Plus Chemotherapy in Advanced Cervical Cancer
NCT05998941Phase 2Withdrawn
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Immunotoxins, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2868 in Cervical Cancer (CC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Aug 2023; status: withdrawn.
02
Drugs
TQB2868
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05998941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05998941.